Documenti analoghi

• Predictors of potential clinically harmful drug–drug interactions at the medical wards in the University of Benin Teaching Hospital, Benin City
  di: Oseremen Godstime Oriaifo, et al.
  Pubblicazione: (2024)
• Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
  di: Jingcheng Chen, et al.
  Pubblicazione: (2024)
• Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population
  di: Simon Dagenais, et al.
  Pubblicazione: (2024)
• No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
  di: Wonsuk Shin, et al.
  Pubblicazione: (2024)
• A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
  di: Amanda Long, et al.
  Pubblicazione: (2024)